Advancing Cancer Treatment is located in Moultonborough, NH. The organization was established in 2019. According to its NTEE Classification (G12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Voluntary Health Associations & Medical Disciplines and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Advancing Cancer Treatment is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2021, Advancing Cancer Treatment generated $1.5m in total revenue. This organization has experienced exceptional growth, as over the past 3 years, it has increased revenue by an average of 35.4% each year . All expenses for the organization totaled $1.2m during the year ending 12/2021. While expenses have increased by 31.7% per year over the past 3 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2020, Advancing Cancer Treatment has awarded 14 individual grants totaling $1,616,542. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2021
Describe the Organization's Mission:
Part 3 - Line 1
ACT'S MISSION IS TO MAKE THE WASHINGTON, DC METROPOLITAN AREA A LEADER IN ADVANCING CLINICAL TRIAL ACCRUAL, THUS ACCELERATING IMPROVED CANCER CARE AND TREATMENT.
Describe the Organization's Program Activity:
Part 3 - Line 4a
ACT'S CURRENT FOCUS IS IMPROVING ACCRUAL TO PROSTATE CANCER CLINICAL TRIALS. ACT'S GOAL IS TO CREATE A PROSTATE REGISTRY AIMED AT GETTING A SIGNIFICANT PORTION OF PROSTATE CANCER PATIENTS TO SIGN UP TO PARTICIPATE BY SUBMITTING A SIMPLE SALIVA TEST THAT WILL PROVIDE THEIR GENETIC INFORMATION FOR RESEARCH, AND PROVIDE AN ALERT SERVICE TO THEM IF ANY TREATMENTS OR THERAPIES MATCH THEIR PROFILE AND COULD HELP CHANGE THEIR OUTCOME.
ACT'S CURRENT FOCUS IS IMPROVING ACCRUAL TO PROSTATE CANCER CLINICAL TRIALS. ACT'S GOAL IS TO CREATE A PROSTATE REGISTRY AIMED AT GETTING A SIGNIFICANT PORTION OF PROSTATE CANCER PATIENTS TO SIGN UP TO PARTICIPATE BY SUBMITTING A SIMPLE SALIVA TEST THAT WILL PROVIDE THEIR GENETIC INFORMATION FOR RESEARCH, AND PROVIDE AN ALERT SERVICE TO THEM IF ANY TREATMENTS OR THERAPIES MATCH THEIR PROFILE AND COULD HELP CHANGE THEIR OUTCOME.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Pamela Brown Vice President, Secretary | OfficerTrustee | 0.2 | $0 |
David Brown President, Treasurer | OfficerTrustee | 0.2 | $0 |
Jenny B Aragon-Ching MD Director | Trustee | 0.2 | $0 |
Donald L Trump MD Director | Trustee | 0.2 | $0 |
Adam R Metwalli MD Director | Trustee | 0.2 | $0 |
Robert Grossman Director | Trustee | 0.2 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $1,500,000 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,500,000 |
Total Program Service Revenue | $0 |
Investment income | $77 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $1,500,077 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $159,000 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation of current officers, directors, key employees. | $0 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $0 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $0 |
Payroll taxes | $0 |
Fees for services: Management | $0 |
Fees for services: Legal | $1,428 |
Fees for services: Accounting | $8,150 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $1,040,122 |
Advertising and promotion | $87,421 |
Office expenses | $1,898 |
Information technology | $0 |
Royalties | $0 |
Occupancy | $0 |
Travel | $788 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $2,333 |
All other expenses | $800 |
Total functional expenses | $1,220,509 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $1,175,149 |
Savings and temporary cash investments | $21 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $1,073 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $1,176,243 |
Accounts payable and accrued expenses | $436,377 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $436,377 |
Net assets without donor restrictions | $739,866 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $1,176,243 |
Over the last fiscal year, Advancing Cancer Treatment has awarded $308,500 in support to 8 organizations.
Grant Recipient | Amount |
---|---|
SIDNEY KIMMEL COMP CANCER CTR PURPOSE: RESEARCH | $75,000 |
SIDNEY KIMMEL COMP CANCER CTR PURPOSE: RESEARCH | $75,000 |
Alexandria, VA PURPOSE: RESEARCH | $30,000 |
Alexandria, VA PURPOSE: RESEARCH | $30,000 |
Chapel Hill, NC PURPOSE: RESEARCH | $28,000 |
UNIVERSITY OF KANSAS MED CTR PURPOSE: RESEARCH | $25,000 |
Over the last fiscal year, we have identified 1 grants that Advancing Cancer Treatment has recieved totaling $800,000.
Awarding Organization | Amount |
---|---|
Fidelity Investments Charitable Gift Fund Boston, MA PURPOSE: For grant recipient's exempt purposes | $800,000 |
Organization Name | Assets | Revenue |
---|---|---|
Integrate Health Inc Medway, MA | $11,519,968 | $5,602,759 |
Neuroendocrine Tumor Research Foundation Boston, MA | $26,608,419 | $8,207,303 |
Cure Rare Disease Inc Boston, MA | $1,470,434 | $2,486,822 |
Advancing Cancer Treatment Moultonborough, NH | $1,176,243 | $1,500,077 |
Why Me Inc Worcester, MA | $5,740,285 | $1,202,450 |
Annies Angels Memorial Fund Inc Stratham, NH | $346,702 | $513,244 |
Lucys Love Bus Charitable Trust Amesbury, MA | $740,985 | $775,660 |
Vision-Aid Incorporated Lexington, MA | $719,092 | $486,957 |
S D Ireland Cancer Research Fund Inc South Burlington, VT | $728,806 | $662,125 |
Teamsters Local 25 Autism Fund Inc Boston, MA | $1,007,428 | $27,638 |
Robin Kaplan Memorial Fund Westborough, MA | $13,321 | $260,588 |
Harbor To The Bay Inc Boston, MA | $31,064 | $255,835 |